Finally, as somatostatin receptor genes (SSTR2, 3 and 5) are putative targets for miR-383, and STAT3 has been proposed as a promising target candidate for pituitary tumor immunotherapy [38], our results might also suggest that miR-383 could be a therapeutic target in corticotroph PitNETs. This evidence concerns the gene SSTR2 and pituitary tumor.